Emm

Cover Block

PUBLIC

Name	Emm
Tagline	Smart menstrual cup with biosensors tracking flow and cycles in real time
Headquarters	Bristol, UK
Founded	2020
Stage	Seed
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$9,000,000)

Links

PUBLIC

• Website: https://www.emm.co
• LinkedIn: https://uk.linkedin.com/company/your-emm

Executive Summary

PUBLIC Emm is building a hardware-first data platform for menstrual health, a category historically reliant on subjective user logs, with a $9 million seed round led by Lunar Ventures signaling investor conviction in the unmet need [TechCrunch, November 2025]. Founder Jenny Button conceived the idea during the COVID-19 lockdown, observing that her Oura ring and Whoop band tracked general wellness but offered no objective data on reproductive cycles, a gap she spent the next five years addressing through thousands of design iterations [SeedCue, November 2025]. The core product is a reusable, medical-grade silicone menstrual cup embedded with ultra-thin biosensors that measure flow volume and cycle metrics in real time, syncing data to a companion app for personalized pattern tracking [TechCrunch, November 2025]. The company operates a direct-to-consumer model and is in a pre-launch phase, targeting a UK rollout in early 2026 followed by a US entry in 2027 [SetSquared, November 2025]. Over the next 12-18 months, the key milestones to watch are the commercial launch execution, any disclosed clinical validation for the sensor data, and the company's ability to navigate the regulatory and privacy hurdles inherent to intimate biowearables.

Data Accuracy: GREEN -- Confirmed by multiple independent sources including TechCrunch, SeedCue, and SetSquared.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$9,000,000)

Company Overview

PUBLIC The company's origin is a hardware story, defined by a five-year development cycle that began with a founder's personal frustration. Jenny Button conceived Emm during the COVID-19 lockdown in 2020 while using consumer wearables like the Oura ring and Whoop, which tracked general health metrics but provided no objective data on menstrual cycles [TechCrunch, November 2025]. This gap led her to contact an engineer at Dyson to begin prototyping, a process that reportedly involved thousands of design iterations and extended user testing before the seed round announcement [SeedCue, November 2025].

Emm is headquartered in Bristol, UK, and was founded in 2020 [Crunchbase]. The company's primary public milestone remains its oversubscribed $9 million seed round in November 2025, led by Lunar Ventures [TechCrunch, November 2025]. A planned UK product launch was targeted for early 2026, with a U.S. entry slated for early 2027 [TechCrunch, November 2025]. As of May 2026, no public announcement confirms the UK launch has occurred, leaving the company in a pre-launch phase.

Data Accuracy: GREEN -- Confirmed by Crunchbase, TechCrunch, and SeedCue.

Product and Technology

MIXED

Emm's product is a hardware-first approach to a persistent data gap in women's health. The core device is a reusable menstrual cup made from medical-grade silicone, distinguished by integrated ultra-thin biosensors that measure flow volume, cycle length, frequency, and regularity in real time [TechCrunch, November 2025]. This positions it as an objective data capture tool, moving beyond the subjective symptom logging that characterizes most cycle-tracking applications. The cup is designed for up to 12 hours of use and recharges between cycles, according to product descriptions [Perplexity Sonar].

Data syncs via Bluetooth to a companion smartphone application. The app's stated function is to provide personalized health insights by establishing a user's baseline over an initial three-cycle period, after which it can identify and track patterns [SeedCue, November 2025]. The company's public messaging emphasizes a commitment to data privacy, with on-device processing mentioned as a feature [SetSquared, November 2025]. The technology stack underlying the sensor fusion, data transmission, and app infrastructure is not detailed in public materials, but the presence of a Senior Electronics Engineer and a Clinical Research and Partnerships Manager on the team page suggests depth in hardware integration and biomedical validation [emm.co/products/emm-smart-cup, 2026].

As of the most recent coverage in November 2025, the product was in pre-launch with a waitlist open for a UK rollout targeted for early 2026 [TechCrunch, November 2025] [SeedCue, November 2025]. No subsequent launch announcement or detailed technical specifications, such as sensor type or battery life, have been published. The five-year development cycle cited by the founder involved thousands of design iterations and user testing, indicating a focus on form factor and usability [SeedCue, November 2025].

Data Accuracy: YELLOW -- Core product claims are consistently reported across multiple news outlets, but detailed technical specifications and post-funding launch updates are not publicly available.

Market Research

PUBLIC

The market for objective, hardware-based menstrual health data is emerging from a convergence of consumer demand for personalized health tracking and a long-standing clinical data gap in women's medicine.

A formal TAM, SAM, or SOM for smart menstrual cups is not available in cited sources. The broader femtech market, however, provides a relevant analog. The global femtech market was valued at approximately $51 billion in 2022 and is projected to reach $103 billion by 2030, according to a report from Grand View Research [Grand View Research]. The segment for menstrual health solutions, which includes apps, wearables, and traditional products, represents a significant portion of this growing category.

Femtech Market 2022 | 51 | $B
Femtech Market 2030 (projected) | 103 | $B

The projected near-doubling of the femtech market over an eight-year period signals strong underlying demand drivers. These include increased consumer investment in health and wellness technology, a growing willingness to share personal health data for insights, and a rising focus on women's health from both public health bodies and private investors. The specific demand for menstrual cycle data is underscored by the widespread adoption of cycle-tracking apps, which rely on user-reported symptoms rather than objective biometrics [TechCrunch, November 2025].

Adjacent and substitute markets are significant. The primary substitute is the established market for disposable menstrual products, valued in the tens of billions globally. The reusable menstrual cup market itself is a smaller but growing niche, with some analysts projecting it to reach over $1 billion by 2027. A more direct adjacent market is the broader consumer health wearables sector, including smart rings and wristbands from companies like Oura and Whoop, which track metrics like heart rate and sleep but have historically excluded dedicated menstrual health monitoring [TechCrunch, November 2025].

Regulatory and macro forces present both tailwinds and hurdles. Positive momentum comes from increased public and private funding for women's health research and a regulatory environment in regions like the EU and UK that is increasingly supportive of digital health innovations. However, any device that collects and interprets health data for potential diagnostic purposes, as Emm's long-term vision suggests, will eventually face medical device regulatory scrutiny (e.g., FDA, CE marking). The company's commitment to data privacy, highlighted in its funding announcement, is a direct response to this macro concern [SetSquared, November 2025].

Data Accuracy: YELLOW -- Market sizing is based on analogous third-party reports for the broader femtech category; specific segment data for smart menstrual hardware is not publicly confirmed.

Competitive Landscape

MIXED Emm enters a market defined by established consumer tracking habits and nascent clinical-grade hardware, positioning its smart cup as a direct measurement tool against a backdrop of symptom-logging apps and traditional menstrual products.

The competitive analysis proceeds on a segment basis.

The competitive map for menstrual health data splits into three distinct tiers. First, the broad consumer digital health and period tracking apps, such as Clue and Flo, represent the incumbent user behavior. These platforms have tens of millions of users and deep datasets on self-reported symptoms and cycle predictions [TechCrunch, November 2025]. However, they rely on manual input, creating a gap for objective, hardware-measured flow data which is Emm's stated wedge. Second, adjacent hardware substitutes include general wellness wearables like the Oura ring, which inspired founder Jenny Button but lack dedicated reproductive health sensors [SLGuardian]. Third, the physical product incumbents are the multi-billion dollar market for disposable pads, tampons, and non-smart reusable cups, where giants like Procter & Gamble (Tampax) and Essity (Libresse) dominate retail shelves but offer no data layer.

Emm's defensible edge today rests on its first-mover status in a specific hardware category and its investor-backed technical development. The five-year development cycle with "thousands of designs and iterations" suggests non-trivial engineering hurdles in miniaturizing biosensors for a fluid environment, which could create a short-term technical moat [SeedCue, November 2025]. Furthermore, the investor lineup provides strategic capital: Lunar Ventures brings hardware expertise, while angels like Harpreet Rai (former Oura CEO) and Amar Shah (Wayve) offer wearables and deep tech networks [SetSquared, November 2025]. The partnership with Labcorp Venture Fund is a public signal of intent toward clinical validation, a channel most consumer apps cannot easily access. This edge is perishable, however, if a well-capitalized incumbent like Apple (with its HealthKit ecosystem and hardware prowess) or a femtech leader like Clue decides to develop or acquire similar sensor technology.

The company's most significant exposure is not to a named startup competitor, but to market adoption risks and potential regulatory scrutiny. Without a commercial launch as of May 2026, Emm has yet to prove consumer willingness to pay a premium for a smart cup over a $30 standard cup or a free app. Its go-to-market is a direct-to-consumer hardware play, a channel it does not own and where customer acquisition costs are notoriously high. Furthermore, as a biosensor collecting intimate health data, it will face heightened privacy regulations (GDPR, potential FDA Class II device classification for the US launch) that could slow rollout and increase compliance overhead relative to software-only competitors.

The most plausible 18-month scenario hinges on execution of the UK launch and early user data. If Emm successfully ships in early 2026, gathers positive initial reviews, and begins generating proprietary flow datasets, it could become the de facto hardware standard for clinical menstrual research, locking in partnerships. The winner in this scenario would be Emm, securing a defensible niche as the hardware data layer for reproductive health. The loser would be the broader cohort of symptom-tracking apps, which would face pressure to integrate objective data sources or risk being viewed as incomplete. Conversely, if the launch is delayed or the hardware faces reliability issues, the window for a well-funded competitor to enter widens significantly.

Data Accuracy: YELLOW -- Competitive mapping is inferred from market context; no direct competitor names are confirmed in sources. Product differentiation and investor edge are corroborated by multiple press reports.

Opportunity

PUBLIC

Emm's opportunity is to become the first hardware platform to generate objective, longitudinal menstrual health data at scale, creating a new asset class for both consumer health and clinical research.

The headline opportunity is the establishment of Emm as the category-defining data standard for female reproductive health. The company is not merely selling a better menstrual cup. It is building the first continuous, quantitative dataset on a fundamental biological process that has historically been tracked through subjective self-reporting. The evidence that this outcome is reachable, rather than aspirational, lies in the composition of its seed round. The participation of Labcorp Venture Fund, a strategic arm of a global diagnostics leader, and Harpreet Rai, the former CEO of Oura, signals a belief from data-centric incumbents that this type of biosensor-generated data holds tangible value [TechCrunch, November 2025]. The five-year development cycle, involving thousands of design iterations, suggests a focus on foundational hardware reliability necessary for clinical-grade data collection [SeedCue, November 2025].

Multiple concrete paths could drive this platform to massive scale. The scenarios below outline distinct, plausible growth vectors, each with a specific catalyst grounded in the company's stated positioning or investor alignment.

Scenario	What happens	Catalyst	Why it's plausible
Clinical Research Partner	Emm devices become a standard tool in pharmaceutical and academic studies for conditions like endometriosis, PCOS, and fertility treatments.	A published peer-reviewed study validating Emm's flow and cycle data against established clinical measures.	The Labcorp Venture Fund investment explicitly ties Emm to the clinical diagnostics ecosystem, indicating a strategic interest in research applications [SetSquared, November 2025].
Consumer Health Subscription	The companion app evolves into a paid subscription service offering advanced predictive analytics, personalized care plans, and integration with broader health ecosystems.	The launch of a premium tier following the establishment of a baseline user cohort from the initial hardware sale.	The model mirrors Oura's evolution from hardware to a subscription-based insights platform, a path validated by investor Harpreet Rai's involvement [TechCrunch, November 2025].
Enterprise Wellness Mandate	Emm is adopted as a covered benefit by forward-thinking employers and health plans seeking to address women's health disparities and reduce related absenteeism.	A pilot program with a large, visible employer in the UK or US, demonstrating cost savings and employee satisfaction metrics.	The growing focus on femtech in corporate benefits, combined with Emm's hardware-as-a-service potential, creates a logical B2B2C expansion route.

Compounding for Emm would manifest as a data network effect. Each new user contributes to a proprietary dataset that improves the algorithm's predictive accuracy for cycle patterns and flow anomalies. This improved accuracy increases the value of the insights for all users, strengthening retention and justifying a premium service tier. For the clinical research path, early validation studies would lower the barrier for adoption in subsequent trials, creating a reinforcing loop where more studies deploy Emm, generating more diverse data that further refines the product for both research and consumer use. The flywheel's first turn is the collection of baseline data over three cycles, a design feature already built into the app's functionality [SeedCue, November 2025].

The size of the win can be framed by looking at comparable platforms in adjacent wearable categories. Oura, a smart ring focused on sleep and recovery, reached a valuation of $2.55 billion in its 2022 funding round [Bloomberg, April 2022]. While not a direct comparison, it demonstrates the valuation potential for a hardware-centric health data platform with a subscription overlay. If Emm successfully executes the "Clinical Research Partner" scenario and captures a material portion of the multi-billion dollar women's health clinical trials market, while layering on a consumer subscription business, a multi-billion dollar outcome is within the realm of possibility (scenario, not a forecast). The company's initial $9 million seed provides the capital to begin validating these pathways toward that scale.

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited investor strategy, product design, and comparable company valuations; specific catalysts and flywheel mechanics are inferred from the company's positioning.

Sources

PUBLIC

1. [TechCrunch, November 2025] Emm raises $9M seed to create one of the world's first smart menstrual cups | https://techcrunch.com/2025/11/18/emm-raises-9m-seed-to-create-to-launch-one-of-the-worlds-first-smart-menstrual-cups/

2. [Crunchbase] Emm - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/emm-126f

3. [SeedCue, November 2025] Emm raises over $9 million to launch world's first smart menstrual solution | https://www.seedcue.com/post/emm-raises-over-9-million-to-launch-worlds-first-smart-menstrual-solution

4. [SetSquared, November 2025] Emm raises over $9 million (£6.8m) to launch world's first smart menstrual solution | https://www.setsquared.co.uk/emm-raises-over-9-million-6-8m-to-launch-worlds-first-smart-menstrual-solution/

5. [Perplexity Sonar] Research Brief | (URL not provided for the brief itself; citations within the brief point to other listed sources)

6. [emm.co/products/emm-smart-cup, 2026] Product Team Page | https://www.emm.co/products/emm-smart-cup/

7. [SLGuardian] Founder Profile | (URL not provided in structured facts)

8. [Grand View Research] Femtech Market Size Report | (URL not provided in structured facts; market sizing data cited from this publisher)

9. [Bloomberg, April 2022] Oura Valuation Report | (URL not provided in structured facts; valuation data cited from this publisher)